Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid) (original) (raw)

References

  1. Dannenberg AM Jr, Thomashefski JF Jr (1988) Pathogenesis of pulmonary tuberculosis. In: Fishman AP (ed) Pulmonary diseases and disorders, 2nd edn, vol 3. McGraw-Hill, New York, p 1821
    Google Scholar
  2. Delabie J, Dewolf-Peters C, Van Den Oord JJ, Desmet J (1990) Differential expression of the calcium-binding proteins MRP8 and MRP14 in granulomatous conditions: an immunohistochemical study. Clin Exp Immunol 81: 123
    Google Scholar
  3. Deodhar S (1989) Regulation of expression of the cell adhesion receptors, integrins, by recombinant human interleukin-1β in human osteosarcoma cells: Inhibition of cell proliferation and stimulation of alkaline phosphatase activity. J Cell Physiol 138: 291
    Google Scholar
  4. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5: 21
    Google Scholar
  5. Fidler IJ (1985) Macrophages and metastasis: a biological approach to cancer therapy. Cancer Res 45: 4714
    Google Scholar
  6. Fidler IJ (1986) Immunomodulation of macrophages for cancer and antiviral therapy. In: Tomlinson E, Davis SS (eds) Site-specific drug delivery. Wiley, New York, p 111
    Google Scholar
  7. Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Gubelski P, Poste G (1982) Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res 42: 496
    Google Scholar
  8. Fidler IJ, Sone S, Fogler WE, Barnes Z (1982) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Yearbook of cancer.
  9. Giavazzi R, Bucana CD, Hart IR (1984) Correlation of tumor growth inhibitory activity of macrophages exposed to Adriamycin and Adriamycin sensitivity of the target tumor cells. J Natl Cancer Inst 73: 447
    Google Scholar
  10. Goorin AM, Perez-Atayde A, Gebhardt M, Anderson JW, Wilkinson RH, Delorey MJ, Watts H, Link M, Jaffe N, Frei E III, Abelson HT (1987) Weekly high-dose methotrexate and doxorubicin for osteosarcoma: The Dana-Farber Cancer Institute/The Children's Hospital Study III. J Clin Oncol 5: 1178
    Google Scholar
  11. Key ME, Talmadge JE, Fogler WE, Bucana CD, Fidler IJ (1982) Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst 69: 1189
    Google Scholar
  12. Kindler V, Sappino A-P, Grau GE, Piguet P-F, Vassalli P (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56: 731
    Google Scholar
  13. Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ (1983) Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 43: 2010
    Google Scholar
  14. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ (1989) Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49: 4665
    Google Scholar
  15. Kleinerman ES, Snyder JS, Jaffe N (1991) Influence of chemotherapy administration on monocyte activation by liposomal MTP-PE in children with osteosarcoma. J Clin Oncol 9: 259
    Google Scholar
  16. Lachman LB, Dinarello CA, Llansa ND, Fidler IJ (1986) Natural and recombinant human interleukin 1-β is cytotoxic for human melanoma cells. J Immunol 136: 3098
    Google Scholar
  17. Link MP, Goorin AM, Miser AW, Green AA, Pratt CG, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson UT, Simone JV, Vietti TJ (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600
    Google Scholar
  18. Lovett D, Kozan B, Hadam M, Resch K, Gemsa D (1986) Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol 136: 340
    Google Scholar
  19. MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howar PE (1989) Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81: 935
    Google Scholar
  20. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lumki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ, Krakoff I (1989) Phase I trial of liposomal muramyl tripeptide phosphatidyl-ethanolamine in cancer patients. J Clin Oncol 7: 1915
    Google Scholar
  21. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, Gerhard SG, Schlegel R, Sorg C (1987) Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 330: 80
    Google Scholar
  22. Old LJ (1985) Tumor necrosis factor (TNF). Science 230: 630
    Google Scholar
  23. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ (1985) Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 135: 3962
    Google Scholar
  24. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ (1982) Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 42: 1412
    Google Scholar
  25. Putnam JB Jr, Roth JA, Wesley MN, Johnston MR, Rosenberg SA (1984) Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 87: 260
    Google Scholar
  26. Schroit AJ, Fidler IJ (1982) Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 43: 161
    Google Scholar
  27. Sone S, Utsugi T, Tandon P, Ogawara M (1986) A dried preparation of liposomes containing muramyl tripeptide phosphatidylehtanolamine as a potent activator of human blood monocytes to the antitumor state. Cancer Immunol Immunother 22: 191
    Google Scholar
  28. Sugarman BJ, Aggarwal BB, Hass PE, Figari MA, Palladino MA Jr, Shepard HM (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943
    Google Scholar
  29. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H (1986) Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA 83: 5233
    Google Scholar
  30. Van Hoogevest P, Fankhauser P (1989) An industrial liposomal dosage form for muramyl-tripeptide-phosphatidylethanolamine (MTP-PE). In: Lopez-Berestein G, Fidler IJ (eds) Liposomes in the therapy of infectious diseases and cancer. Liss, New York, p 453
    Google Scholar
  31. Wold LE, Unni KK, Beabout JW, Sim FH, Dahlin DC (1984) Dedifferentiated parosteal osteosarcoma. J Bone Joint Surg 66[A]: 53
    Google Scholar

Download references